Delayed treatment with a small pigment epithelium derived factor (PEDF) peptide prevents the progression of diabetic renal injury

Alaa S. Awad, Hanning You, Ting Gao, Anzor Gvritishvili, Timothy K. Cooper, Joyce Tombran-Tink

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Our recent publication showed that a small bioactive pigment epithelium derived factor (PEDF) peptide (P78-PEDF) prevents the development of diabetic nephropathy (DN). However, its effects on the progression of established DN were not clear. Therefore, the purpose of this study was to determine the effect of P78-PEDF in the progression of DN and to compare the effects of P78-PEDF and an ACE inhibitor (ACEi), a standard of care in DN. Experiments were conducted in Ins2Akita mice treated with P78-PEDF or captopril starting at 6 wks of age for 12 wks (early treatment) or starting at 12 wks of age for 6 wks (late treatment). We first established the optimal dose of the P78-PEDF peptide to ameliorate DN in Ins2Akita mouse for a 6 wk study period and found that the peptide was effective at 0.1-0.5 μg/g/day. We next showed that early or late treatment with P78-PEDF resulted in protection from DN as indicated by reduced albuminuria, kidney macrophage recruitment, histological changes, inflammatory cytokines and fibrotic markers (kidney TNF-α, fibronectin, VEGFA and EGFR), and restored nephrin expression compared with vehicle-Treated Ins2Akita mice. Interestingly, only early but not late treatment with captopril was as effective as P78-PEDF in reducing most DN complications, despite its lack of effect on nephrin, VEGFA and EGFR expression. These findings highlight the importance of P78-PEDF peptide as a potential therapeutic modality in both the development and progression of diabetic renal injury.

Original languageEnglish (US)
Article numbere0133777
JournalPloS one
Volume10
Issue number7
DOIs
StatePublished - Jul 24 2015

Fingerprint

diabetic nephropathy
Diabetic Nephropathies
epithelium
pigments
kidneys
peptides
Kidney
Peptides
Wounds and Injuries
Captopril
mice
pigment epithelium-derived factor
Albuminuria
fibronectins
Macrophages
Diabetes Complications
Standard of Care
Fibronectins
Angiotensin-Converting Enzyme Inhibitors
macrophages

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Awad, Alaa S. ; You, Hanning ; Gao, Ting ; Gvritishvili, Anzor ; Cooper, Timothy K. ; Tombran-Tink, Joyce. / Delayed treatment with a small pigment epithelium derived factor (PEDF) peptide prevents the progression of diabetic renal injury. In: PloS one. 2015 ; Vol. 10, No. 7.
@article{9d7a8859c2b149b4a43197e957a630c0,
title = "Delayed treatment with a small pigment epithelium derived factor (PEDF) peptide prevents the progression of diabetic renal injury",
abstract = "Our recent publication showed that a small bioactive pigment epithelium derived factor (PEDF) peptide (P78-PEDF) prevents the development of diabetic nephropathy (DN). However, its effects on the progression of established DN were not clear. Therefore, the purpose of this study was to determine the effect of P78-PEDF in the progression of DN and to compare the effects of P78-PEDF and an ACE inhibitor (ACEi), a standard of care in DN. Experiments were conducted in Ins2Akita mice treated with P78-PEDF or captopril starting at 6 wks of age for 12 wks (early treatment) or starting at 12 wks of age for 6 wks (late treatment). We first established the optimal dose of the P78-PEDF peptide to ameliorate DN in Ins2Akita mouse for a 6 wk study period and found that the peptide was effective at 0.1-0.5 μg/g/day. We next showed that early or late treatment with P78-PEDF resulted in protection from DN as indicated by reduced albuminuria, kidney macrophage recruitment, histological changes, inflammatory cytokines and fibrotic markers (kidney TNF-α, fibronectin, VEGFA and EGFR), and restored nephrin expression compared with vehicle-Treated Ins2Akita mice. Interestingly, only early but not late treatment with captopril was as effective as P78-PEDF in reducing most DN complications, despite its lack of effect on nephrin, VEGFA and EGFR expression. These findings highlight the importance of P78-PEDF peptide as a potential therapeutic modality in both the development and progression of diabetic renal injury.",
author = "Awad, {Alaa S.} and Hanning You and Ting Gao and Anzor Gvritishvili and Cooper, {Timothy K.} and Joyce Tombran-Tink",
year = "2015",
month = "7",
day = "24",
doi = "10.1371/journal.pone.0133777",
language = "English (US)",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

Delayed treatment with a small pigment epithelium derived factor (PEDF) peptide prevents the progression of diabetic renal injury. / Awad, Alaa S.; You, Hanning; Gao, Ting; Gvritishvili, Anzor; Cooper, Timothy K.; Tombran-Tink, Joyce.

In: PloS one, Vol. 10, No. 7, e0133777, 24.07.2015.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Delayed treatment with a small pigment epithelium derived factor (PEDF) peptide prevents the progression of diabetic renal injury

AU - Awad, Alaa S.

AU - You, Hanning

AU - Gao, Ting

AU - Gvritishvili, Anzor

AU - Cooper, Timothy K.

AU - Tombran-Tink, Joyce

PY - 2015/7/24

Y1 - 2015/7/24

N2 - Our recent publication showed that a small bioactive pigment epithelium derived factor (PEDF) peptide (P78-PEDF) prevents the development of diabetic nephropathy (DN). However, its effects on the progression of established DN were not clear. Therefore, the purpose of this study was to determine the effect of P78-PEDF in the progression of DN and to compare the effects of P78-PEDF and an ACE inhibitor (ACEi), a standard of care in DN. Experiments were conducted in Ins2Akita mice treated with P78-PEDF or captopril starting at 6 wks of age for 12 wks (early treatment) or starting at 12 wks of age for 6 wks (late treatment). We first established the optimal dose of the P78-PEDF peptide to ameliorate DN in Ins2Akita mouse for a 6 wk study period and found that the peptide was effective at 0.1-0.5 μg/g/day. We next showed that early or late treatment with P78-PEDF resulted in protection from DN as indicated by reduced albuminuria, kidney macrophage recruitment, histological changes, inflammatory cytokines and fibrotic markers (kidney TNF-α, fibronectin, VEGFA and EGFR), and restored nephrin expression compared with vehicle-Treated Ins2Akita mice. Interestingly, only early but not late treatment with captopril was as effective as P78-PEDF in reducing most DN complications, despite its lack of effect on nephrin, VEGFA and EGFR expression. These findings highlight the importance of P78-PEDF peptide as a potential therapeutic modality in both the development and progression of diabetic renal injury.

AB - Our recent publication showed that a small bioactive pigment epithelium derived factor (PEDF) peptide (P78-PEDF) prevents the development of diabetic nephropathy (DN). However, its effects on the progression of established DN were not clear. Therefore, the purpose of this study was to determine the effect of P78-PEDF in the progression of DN and to compare the effects of P78-PEDF and an ACE inhibitor (ACEi), a standard of care in DN. Experiments were conducted in Ins2Akita mice treated with P78-PEDF or captopril starting at 6 wks of age for 12 wks (early treatment) or starting at 12 wks of age for 6 wks (late treatment). We first established the optimal dose of the P78-PEDF peptide to ameliorate DN in Ins2Akita mouse for a 6 wk study period and found that the peptide was effective at 0.1-0.5 μg/g/day. We next showed that early or late treatment with P78-PEDF resulted in protection from DN as indicated by reduced albuminuria, kidney macrophage recruitment, histological changes, inflammatory cytokines and fibrotic markers (kidney TNF-α, fibronectin, VEGFA and EGFR), and restored nephrin expression compared with vehicle-Treated Ins2Akita mice. Interestingly, only early but not late treatment with captopril was as effective as P78-PEDF in reducing most DN complications, despite its lack of effect on nephrin, VEGFA and EGFR expression. These findings highlight the importance of P78-PEDF peptide as a potential therapeutic modality in both the development and progression of diabetic renal injury.

UR - http://www.scopus.com/inward/record.url?scp=84941729964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941729964&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0133777

DO - 10.1371/journal.pone.0133777

M3 - Article

C2 - 26207369

AN - SCOPUS:84941729964

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e0133777

ER -